Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer

Yuji Miyamoto, Eiji Oki, Yasunori Emi, Shoji Tokunaga, Mototsugu Shimokawa, Yutaka Ogata, Yoshito Akagi, Yasuo Sakamoto, Takaho Tanaka, Hiroshi Saeki, Yoshihiko Maehara, Hideo Baba

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. Results: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). Conclusion: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC.

Original languageEnglish
Pages (from-to)491-499
Number of pages9
JournalAnticancer research
Volume38
Issue number1
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Intra-Abdominal Fat
Colorectal Neoplasms
Survival
Confidence Intervals
Bevacizumab
Drug Therapy
Multivariate Analysis
Tomography

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer. / Miyamoto, Yuji; Oki, Eiji; Emi, Yasunori; Tokunaga, Shoji; Shimokawa, Mototsugu; Ogata, Yutaka; Akagi, Yoshito; Sakamoto, Yasuo; Tanaka, Takaho; Saeki, Hiroshi; Maehara, Yoshihiko; Baba, Hideo.

In: Anticancer research, Vol. 38, No. 1, 01.2018, p. 491-499.

Research output: Contribution to journalArticle

Miyamoto, Y, Oki, E, Emi, Y, Tokunaga, S, Shimokawa, M, Ogata, Y, Akagi, Y, Sakamoto, Y, Tanaka, T, Saeki, H, Maehara, Y & Baba, H 2018, 'Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer', Anticancer research, vol. 38, no. 1, pp. 491-499. https://doi.org/10.21873/anticanres.12249
Miyamoto, Yuji ; Oki, Eiji ; Emi, Yasunori ; Tokunaga, Shoji ; Shimokawa, Mototsugu ; Ogata, Yutaka ; Akagi, Yoshito ; Sakamoto, Yasuo ; Tanaka, Takaho ; Saeki, Hiroshi ; Maehara, Yoshihiko ; Baba, Hideo. / Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer. In: Anticancer research. 2018 ; Vol. 38, No. 1. pp. 491-499.
@article{23753a2995c44f4391ab4aac4217c7c9,
title = "Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer",
abstract = "Aim: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. Results: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95{\%} confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95{\%} confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). Conclusion: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC.",
author = "Yuji Miyamoto and Eiji Oki and Yasunori Emi and Shoji Tokunaga and Mototsugu Shimokawa and Yutaka Ogata and Yoshito Akagi and Yasuo Sakamoto and Takaho Tanaka and Hiroshi Saeki and Yoshihiko Maehara and Hideo Baba",
year = "2018",
month = "1",
doi = "10.21873/anticanres.12249",
language = "English",
volume = "38",
pages = "491--499",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer

AU - Miyamoto, Yuji

AU - Oki, Eiji

AU - Emi, Yasunori

AU - Tokunaga, Shoji

AU - Shimokawa, Mototsugu

AU - Ogata, Yutaka

AU - Akagi, Yoshito

AU - Sakamoto, Yasuo

AU - Tanaka, Takaho

AU - Saeki, Hiroshi

AU - Maehara, Yoshihiko

AU - Baba, Hideo

PY - 2018/1

Y1 - 2018/1

N2 - Aim: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. Results: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). Conclusion: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC.

AB - Aim: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. Results: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). Conclusion: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC.

UR - http://www.scopus.com/inward/record.url?scp=85039776219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039776219&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12249

DO - 10.21873/anticanres.12249

M3 - Article

C2 - 29277814

AN - SCOPUS:85039776219

VL - 38

SP - 491

EP - 499

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -